4月28日晚，联影医疗(688271)发布2024年ESG报告，从普惠健康、科技创新、绿色运营、企业管理等 多个角度，全面展示公司在ESG各个领域的举措与成果。 此外，联影医疗还在构建全链国产化生态，打造价值型生态供应链，已覆盖原材料层、元器件层到核心 零部件层，完成防散射栅格、化工材料及产品等战略材料的国产替代开发，开发了FPGA、功率半导体 器件、无磁元器件等国产供应商，并突破滑环、高速轴承等精密部件的国产化技术瓶颈。截至2024年 末，联影医疗累计专利申请超9300项，其中累计发明专利申请超7700项：累计专利获得超4600项，其中 累计发明专利获得超3400项。 通过技术赋能与供应链生态共建，联影医疗已形成具有行业示范效应的产业创新集群，培育了近千家优 质国产供应商，其中专精特新"小巨人"企业近百家，助推数十家生态链企业登陆资本市场。 以CT为例，联影医疗全面掌握球管、高压发生器、探测器、高速旋转机架、图像重建算法、高速重建 平台等技术，其中高压发生器已实现从42KW到100KW高中低配置的全部自主研发；2-5MHu球管已实 现全部自主研发及量产；8MHu以上球管研发样管已完成，性能表现优异，正持续优 ...

Market Performance - In 2024, despite external challenges such as global instability and complex trade environments, the company maintained strategic focus and achieved steady market share growth[2]. - The company reported a significant increase in revenue, achieving a year-over-year growth of 25% to reach 1.5 billion RMB in the last quarter[18]. - User data showed a 30% increase in active users, bringing the total to 3 million users across all platforms[19]. - The company provided an optimistic outlook, projecting a revenue growth of 20% for the next fiscal year, driven by new product launches and market expansion[18]. - The company reported a revenue of 1.2 billion CNY for the fiscal year 2023, representing a year-over-year growth of 15%[24]. - The company expects a revenue guidance of 1.5 billion CNY for the fiscal year 2024, indicating a projected growth of 25%[24]. - The company achieved a total revenue of 10.3 billion RMB in 2024, with a year-on-year increase of over 3 percentage points in overall business market share[48]. - The company's overseas business revenue reached 2.266 billion RMB, a year-on-year increase of 35.07%, accounting for 22% of total revenue, marking a historical high[49]. - The company reported total revenue of CNY 10,300,104,386.97 for 2024, a decrease of 9.73% compared to 2023[30]. - The net profit attributable to shareholders was CNY 1,261,869,451.27, down 36.08% year-over-year[30]. Research and Development - The company emphasizes the integration of AI medical models into its core operations, enhancing efficiency and improving patient outcomes across various medical scenarios[3]. - Investment in R&D has increased by 15%, focusing on advanced imaging technologies and AI integration in medical devices[19]. - The company increased its R&D investment to 21.95% of total revenue, up 5.14 percentage points from the previous year[31]. - The company has filed over 9,300 patent applications, with more than 80% being invention patents, and has launched over 140 products, including 49 that received FDA 510(K) approval[45]. - The company’s R&D investment reached 2.261 billion yuan, accounting for 21.95% of total revenue, an increase of 5.14 percentage points year-on-year[54]. - The total R&D investment for the year reached ¥2,260,827,099.47, an increase of 17.84% compared to the previous year[164]. - The number of newly applied patents during the reporting period was 1,079, with 707 patents granted, including 766 invention patents[160]. - The company has a total of 11,502 intellectual property applications, of which 5,882 have been granted[160]. - The company has developed advanced products, including the first 4D whole-body dynamic scanning PET/CT product and the first ultra-high field whole-body imaging MRI[170][171]. Product Development and Innovation - The company has established a comprehensive solution centered around major diseases, creating a closed-loop process from imaging recognition to treatment execution[4]. - The company is committed to long-termism, focusing on the integration of high-end equipment and AI systems to expand the healthcare value chain[6]. - The company is actively collaborating with top medical centers and research institutions to drive original innovation and enhance brand influence globally[4]. - The company is exploring opportunities in telemedicine, with plans to invest 50 million RMB in developing digital health solutions[19]. - The company has established partnerships with leading healthcare providers, aiming to improve service delivery and patient outcomes[19]. - The company launched over 140 innovative products, with 49 receiving FDA 510(k) clearance and 46 obtaining CE MDR/MDD certification[60]. - The company has developed a comprehensive CT product line, ranging from 16-slice to 320-slice systems, catering to diverse needs in disease screening and clinical diagnosis[100]. - The company has introduced multiple superconducting MR products, including the uMR Jupiter 5T, which is the industry's first full-body imaging 5.0T MR model, catering to both clinical and research applications[95]. - The company has developed advanced imaging technologies for precise tumor localization and adaptive radiation therapy, enhancing treatment accuracy[157]. Financial Management - The company has a robust risk management framework in place, ensuring the accuracy and completeness of its financial reports[9]. - Cost optimization strategies have led to a 12% reduction in operational expenses, improving overall profitability[18]. - The company plans to implement cost-cutting measures to improve operational efficiency, targeting a reduction of 5% in operational costs by the end of 2024[24]. - The company experienced a significant drop in cash flow from operating activities, reporting a net cash flow of -CNY 619,024,253.25[30]. - The company faced a 138.57% increase in credit impairment losses, amounting to CNY 140.72 million compared to CNY 58.98 million in the previous year[197]. Market Expansion - The company is expanding its global presence by establishing regional headquarters and R&D centers in countries like the USA, Malaysia, UAE, and the Netherlands, aiming for localized operations[5]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[18]. - The company has completed the acquisition of a smaller imaging technology firm for 300 million CNY to enhance its product portfolio[24]. - The company has established a diverse marketing network covering 85 countries and regions, including the US, Japan, and South Korea[177]. - The company has established 25 overseas subsidiaries and offices to enhance its international sales channels[184]. Sustainability and Compliance - The company’s MSCI ESG rating improved to A, ranking in the top 15% of industry peers in the S&P Global Corporate Sustainability Assessment[47]. - The company set a target to reduce carbon emission intensity by 50% by 2035, using 2023 as the baseline year[88]. - The company provided training for over 16,000 employees on anti-bribery and anti-corruption policies, enhancing its compliance governance[87]. - The company has built a comprehensive intellectual property management system to support risk identification and legal dispute handling[175]. Customer Engagement and Service - The company emphasizes a customer-centric approach with a complete after-sales service system, including training, installation, and maintenance[178]. - The company has a comprehensive after-sales service system, certified by ISO 27001, ISO 13485, and ISO 9001, to improve user experience[126]. - The company conducts regular evaluations and training for distributors to ensure compliance and enhance sales capabilities[126].

上海联影医疗科技股份有限公司 关于使用部分闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海联影医疗科技股份有限公司（以下简称"公司"或"联影医疗"）于 2025 年 4 月 25 日召开第二届董事会第二十次会议、第二届监事会第十二次会 议，审议通过了《关于使用部分闲置募集资金进行现金管理的议案》，同意公司 在确保募集资金投资项目所需资金充足和保证募集资金安全的前提下，合计使 用不超过人民币 400,000 万元(含本数)的闲置募集资金进行现金管理，用于购买 安全性高、流动性好、有保本约定的投资产品，在上述额度范围内，资金可以 滚动使用，使用期限自公司本次董事会审议通过之日起 12 个月内有效。董事会 授权公司董事长或董事长授权人员在上述额度范围及有效期内行使投资决策权 并签署相关合同文件，具体事项由公司财务部负责组织实施，该事项无需提交 股东会审议。 一、募集资金基本情况 证券代码： 688271 证券简称： 联影医疗 公告编号： 2025-011 （二）额度及期限 公司拟使用总额不超过 ...

证券代码： 688271 证券简称： 联影医疗 公告编号： 2025-015 上海联影医疗科技股份有限公司 关于董事辞职及补选董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海联影医疗科技股份有限公司（以下简称"公司"或"联影医疗"）于 2025 年4月25日召开第二届董事会第二十次会议审议通过了《关于补选董事的议案》， 现将公司董事辞职并补选董事的相关情况公告如下： 近日，公司收到丁君先生的辞职报告，因工作原因向公司董事会提出辞去董 事职务，辞职后丁君先生将不再担任公司任何职务。丁君先生对公司 2024 年年 度报告及 2025 年第一季度报告均发表了同意的确认意见，其辞职自 2025 年 4 月 26 日起生效。丁君先生的辞职未导致董事会人数低于法定最低人数，不会影 响公司董事会的正常运作。截至本公告披露日，丁君先生未持有公司股份。丁君 先生确认，其与公司、董事会、监事会之间无任何意见分歧，亦无任何与辞职有 关的事项需提请公司股东注意。丁君先生在职期间恪尽职守、勤勉尽责，为公司 规范和发展做出了积极贡献， ...

证券代码： 688271 证券简称： 联影医疗 公告编号： 2025-013 上海联影医疗科技股份有限公司 关于续聘 2025 年度会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 拟聘任的会计师事务所名称：安永华明会计师事务所（特殊普通合伙） （以下简称"安永华明"） 上海联影医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日 召开第二届董事会第二十次会议审议通过了《关于续聘 2025 年度会计师事务所 的议案》，同意聘任安永华明为公司 2025 年度财务和内部控制审计机构，本议案 尚需提交公司 2024 年年度股东会审议。 一、拟聘任审计机构的基本情况 （一）机构信息 1、基本信息 安永华明于 1992 年 09 月成立，2012 年 08 月完成本土化转制，从一家中外 合作的有限责任制事务所转制为特殊普通合伙制事务所。安永华明总部设在北京， 注册地址为北京市东城区东长安街 1 号东方广场安永大楼 17 层 01-12 室。 2、人员信息 安永华明的首席合伙人为毛 ...

上海联影医疗科技股份有限公司 2024 年度募集资金存放与实际使用情况专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码： 688271 证券简称： 联影医疗 公告编号： 2025-010 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等相 关规定，上海联影医疗科技股份有限公司（以下简称"公司"或"联影医疗"） 将公司 2024 年度募集资金存放与实际使用情况专项报告如下： 一、募集资金基本情况 根据中国证监会核发的《关于同意上海联影医疗科技股份有限公司首次公开 发行股票注册的批复》（证监许可[2022]1327 号），公司获准向社会公开发行人民 币普通股（A 股）10,000 万股，发行价格为 109.88 元/股，募集资金总额 1,098,800 万元。公司募集资金总额扣除所有股票发行费用（包括不含增值税的承销及保荐 费用以及其他发行费用）人民币 264,158,460.63 元后的募集资金净额为人民币 10 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 2,477,948,927.49, representing a 5.42% increase compared to CNY 2,350,478,362.11 in the same period last year[4] - Net profit attributable to shareholders was CNY 370,082,216.76, a 1.87% increase from CNY 363,297,720.56 year-on-year[4] - The net profit after deducting non-recurring gains and losses increased by 26.09% to CNY 378,502,314.92 from CNY 300,194,937.03 in the previous year[4] - Basic earnings per share for Q1 2025 was ¥0.45, up from ¥0.44 in Q1 2024[17] - The total comprehensive income for Q1 2025 was ¥363,235,743.84, slightly up from ¥362,987,690.02 in Q1 2024[16] Cash Flow - The net cash flow from operating activities improved to -CNY 353,474,219.65, compared to -CNY 657,050,656.93 in the same period last year[4] - Cash flow from operating activities in Q1 2025 was negative at -¥353,474,219.65, an improvement from -¥657,050,656.93 in Q1 2024[18] - The net cash flow from investment activities was $42,049,490.76, a significant improvement compared to a negative cash flow of -$1,123,792,938.39 in the previous period[19] - The net cash flow from financing activities was -$9,102,182.39, compared to -$52,965,585.80 in the previous period, indicating a reduced outflow[19] Assets and Liabilities - The total assets at the end of the reporting period were CNY 28,846,018,517.29, a 2.89% increase from CNY 28,035,688,872.48 at the end of the previous year[5] - The company's total liabilities increased to RMB 8,563,210,960.39 from RMB 8,129,447,799.81, which is an increase of about 5.3%[13] - The equity attributable to shareholders reached RMB 20,284,291,823.43, up from RMB 19,903,165,417.53, reflecting a growth of approximately 1.9%[13] - The company's current assets totaled RMB 21,178,583,764.62, compared to RMB 20,893,841,318.46 at the end of 2024, indicating an increase of about 1.37%[12] Research and Development - Research and development expenses totaled CNY 567,853,212.94, up 12.01% from CNY 506,949,927.30, accounting for 22.92% of total revenue[5] - Research and development expenses for Q1 2025 were ¥378,872,051.95, down 9.7% from ¥419,681,857.09 in Q1 2024[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,435[8] - The company received government subsidies amounting to CNY 17,600,465.75 during the period[6] Inventory and Receivables - The company's inventory increased to RMB 6,137,986,392.11 from RMB 5,528,382,408.16, indicating a rise of about 11%[11] - Accounts receivable rose to RMB 4,907,131,343.58 from RMB 4,358,808,221.15, marking an increase of around 12.6%[11] Cash and Cash Equivalents - The cash and cash equivalents decreased to RMB 7,185,525,069.64 from RMB 8,399,997,063.38, representing a decline of approximately 14.5%[11] - The cash and cash equivalents at the end of the period were $5,546,756,540.92, down from $5,867,855,094.11 at the beginning of the period[19] - The company’s cash and cash equivalents decreased by $321,098,553.19 during the period[19] Other Financial Metrics - The weighted average return on equity decreased slightly to 1.84% from 1.91%[5] - Operating profit for Q1 2025 was ¥398,763,564.24, compared to ¥400,407,296.57 in Q1 2024, indicating a decrease of 0.4%[16] - Total operating costs for Q1 2025 were ¥2,132,796,705.76, an increase of 3.8% from ¥2,055,132,564.46 in Q1 2024[15] - Other income for Q1 2025 was ¥115,812,587.45, compared to ¥105,262,737.48 in Q1 2024, reflecting an increase of 10.5%[15] Future Outlook - The company plans to implement new accounting standards starting in 2025, which may affect the financial statements[19]

上海联影医疗科技股份有限公司 关于 2024 年度会计师事务所的履职情况评估报告 （三）上市公司与前后任会计师事务所的沟通情况 根据《国有企业、上市公司选聘会计师事务所管理办法》等相关规范性文件 的规定，上海联影医疗科技股份有限公司（以下简称"公司"）对安永华明会计 师事务所（特殊普通合伙）（以下简称"安永华明"）在 2024 年度的审计工作的 履职情况进行了评估。经评估，公司认为安永华明在资质等方面合规有效，履职 保持独立性，勤勉尽责，公允表达意见。具体情况如下： 一、会计师事务所的基本情况 安永华明于 1992 年 09 月成立，2012 年 08 月完成本土化转制，从一家中外 合作的有限责任制事务所转制为特殊普通合伙制事务所。安永华明总部设在北京， 注册地址为北京市东城区东长安街 1 号东方广场安永大楼 17 层 01-12 室。 安永华明的首席合伙人为毛鞍宁。截至 2023 年 12 月 31 日，安永华明合伙 人人数为 245 人，注册会计师人数为 1,800 人，其中签署过证券服务业务审计报 告的注册会计师近 500 人。 二、前任会计师事务所的情况 （一）前任会计师事务所情况及上年度审计意见 公 ...

上海联影医疗科技股份有限公司 2024 年度 募集资金存放与实际使用情况专项报告 及鉴证报告 目录 上海联影医疗科技股份有限公司董事会： 我们接受委托，对后附的上海联影医疗科技股份有限公司 2024 年度募集资金存放 与实际使用情况的专项报告（"募集资金专项报告"）进行了鉴证。按照《上市公司监 管指引第 2 号——上市公司募集资金管理和使用的监管要求》、《上海证券交易所科创 板上市公司自律监管指引第 1 号——规范运作》及相关格式指南编制募集资金专项报告， 并保证其内容真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏是上海联影 医疗科技股份有限公司董事会的责任。我们的责任是在执行鉴证工作的基础上对募集资 金专项报告独立发表鉴证意见。 页码 | 一、募集资金存放与实际使用情况鉴证报告 | 1 - 2 | | --- | --- | | 二、上海联影医疗科技股份有限公司 2024 年度募集资金 | | | 存放与实际使用情况专项报告 | 3 - 9 | | 三、附表：2024 年度募集资金使用情况对照表 | 10 | 募集资金存放与实际使用情况鉴证报告 安永华明（2025）专字第70030227_B02号 ...